The rapid spread of COVID-19 globally has led to tremendous disruption in the health care industry. We are actively assessing the impact the virus will have on our work at ML Bio Solutions, including the timing of our natural history study and subsequent clinical trials. We are doing our absolute best to minimize any delays, but we know that right now health care institutions and doctors around the world have shifted their focus to emergent COVID-19 cases. Many hospitals and physicians have postponed elective medical procedures and delayed the start of new studies. There is disruption across the country and globe as people are ordered to stay home to slow the spread of the virus. We support these steps, which are needed to minimize the devastating impact of this global pandemic.

Please know that despite these new hurdles we all face, our commitment to patients and their families does not change. That commitment is the cornerstone of our mission at ML Bio Solutions. We exist to bring meaningful medicines to patients as quickly and as safely as possible. But we do have to work within the new reality that is emerging. We are looking at the rapidly changing healthcare landscape on an hour-by-hour basis and trying to minimize disruption to our programs as much as possible.

We are in this together. There will inevitably be delays and we don’t know what the future holds, but we will not stop working as fast as we possibly and safely can for patients. You have our word.

Stay safe.

Douglas Sproule, M.D. M.Sc., CMO ML Bio Solutions
George McLendon, CEO ML Bio Solutions
Neil Kumar, CEO BridgeBio Pharma